TAIPEI and SAN
DIEGO, July 12, 2024 /PRNewswire/ -- Senhwa
Biosciences' new drug Pidnarulex (CX-5461) has demonstrated
efficacy in treating various solid tumors with BRCA2 or PALB2 gene
defects. The abstract of this clinical trial has been selected for
presentation at the 2024 European Society for Medical Oncology
(ESMO) congress. This achievement is a significant milestone for
Senhwa Biosciences and the Canadian clinical team, as it includes
terminal cancer patients who although have undergone various prior
treatments are found in stable condition, continuously receiving
Pidnarulex (CX-5461) treatment in this trial. This highlights that
Pidnarulex (CX-5461) aligns with the trend of developing new drugs
for precision medicine.
![(PRNewsfoto/Senhwa Biosciences, Inc.) (PRNewsfoto/Senhwa Biosciences, Inc.)](https://mma.prnewswire.com/media/1933477/Senhwa_Logo_Logo_Logo.jpg)
The clinical trial is an open-label, multinational, multicenter
study, divided into a Main Study Cohort and an Exploratory Cohort.
The Main Study Cohort includes patients with various tumors
(pancreatic cancer, breast cancer, ovarian cancer, and prostate
cancer) with BRCA2 and/or PALB2 gene defects. The Exploratory
Cohort includes ovarian cancer patients with BRCA1 gene defects
and/or other homologous recombination deficiency (HRD) genes. The
primary objective of the trial is to determine the optimal dose for
patients with specific gene defects while the secondary objectives
are set to assess the safety and tolerability of Pidnarulex
(CX-5461), and to evaluate late-onset toxicity, antitumor activity
as well as improvement in patients' quality of life. Patients
enrolled in this clinical trial have undergone 2 to 10 different
treatment regimens; some of them are even resistant to
platinum-based chemotherapy and PARP inhibitors, leaving no other
treatment options available. Encouragingly, these terminal patients
have shown clinical benefits provided by the Pidnarulex (CX-5461)
treatment.
The 2024 European Society for Medical Oncology (ESMO) Congress
will be held from September 13 to 17,
2024, in Barcelona, Spain,
welcoming both in-person and online participations. This congress
will showcase the latest cutting-edge cancer translational data and
provide a platform for oncology professionals and scientists to
network and share research and innovations. The ESMO Congress is a
cornerstone event in oncology, recognized globally for its
significant contributions to cancer treatment and research. It is
one of the top three cancer medical conferences worldwide,
alongside ASCO and AACR. The abstract for the clinical trial of
Pidnarulex (CX-5461) treating various solid tumors with BRCA1,
BRCA2, and/or PALB2 gene defects (1b)
was written and submitted by the Canadian clinical partner,
Princess Margaret Cancer Centre. The abstract title is expected to
be available online by the end of July, with the full abstract and
related data to be published on September
9.
Senhwa Biosciences' new drug, Pidnarulex (CX-5461), is currently
being applied in breast cancer, ovarian cancer, pancreatic cancer,
hematologic malignancies, and prostate cancer. As a new drug
candidate for solid tumors in collaboration with National
Institutes of Health (NIH), the first stage of clinical trials will
begin in 2024. With the remarkable efforts of NIH's professionals
and medical network, Senhwa Biosciences expects the clinical
outcomes of Pidnarulex (CX-5461) treating multiple cancers will
make significant strides in the fight against various types of
cancer.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/senhwa-biosciences-clinical--data-abstract-of-pidnarulex-accepted-for-presentation-at-2024-esmo-congress-302195586.html
SOURCE Senhwa Biosciences, Inc.